BRIEF—Distribution deal targets rare diseases in South America

Perrigo subsidiary HRA Pharma Rare Diseases has signed a partnership with Celnova Pharma to register and launch products in Argentina, Chile and Peru.

Celnova is a regional drugmaker focused on rare diseases, oncology, central nervous system diseases, diabetes and critical care.

The agreement focuses on two products used to treat the serious rare disease Cushing’s syndrome and a rare type of cancer, adrenocortical carcinoma.

HRA Pharma chief operating officer said the deal would help “make our rare disease treatments available in three important countries in South America,” adding: “This partnership will act as an extension of our longstanding commitment to improving the lives of those with rare diseases.”

Financial particulars were not disclosed.